Gastrointestinal Protection with Ertapenem

Introduction to Ertapenem and Gastrointestinal Risk

The American College of Cardiology and other guideline societies suggest that ertapenem, a carbapenem antibiotic, does not require routine gastric protection with proton pump inhibitors like omeprazol because it does not compromise gastric mucosa integrity or inhibit protective prostaglandin synthesis in patients without additional risk factors 1, 2
Current guidelines for managing intra-abdominal infections do not mention the need for gastric protection when prescribing ertapenem, indicating a low risk of gastrointestinal complications associated with its use 1, 2

The American College of Cardiology recommends the use of proton pump inhibitors like omeprazol primarily for patients receiving nonsteroidal anti-inflammatory drugs (NSAIDs), especially those with risk factors such as advanced age, history of peptic ulcer, or concomitant use of anticoagulants, due to the increased risk of gastrointestinal bleeding 3, 4
Gastric protection is also indicated for patients on antiplatelet therapy, particularly when combined with anticoagulants, due to the elevated risk of gastrointestinal complications 4, 5
The use of corticosteroids, especially when combined with NSAIDs, is another scenario where gastric protection should be considered to mitigate the risk of gastrointestinal adverse effects 3

Patients with a history of peptic ulcer disease, concomitant use of NSAIDs, anticoagulants, or corticosteroids, and advanced age (>65 years) are at higher risk for gastrointestinal complications and may benefit from gastric protection 3, 4, 6

There is no evidence that carbapenem antibiotics like ertapenem increase the risk of gastrointestinal lesions requiring gastric protection, supporting the guideline recommendation against routine use of proton pump inhibitors with ertapenem 1, 2
The potential risks of unnecessary proton pump inhibitor use include an increased risk of nosocomial pneumonia, potential increase in the risk of osteoporotic fractures with long-term use, and alterations in intestinal microbiota 4, 6

The decision to add a proton pump inhibitor should be based on the presence of additional risk factors for gastrointestinal bleeding, not solely on the use of ertapenem, emphasizing a tailored approach to gastric protection 1, 2, 3, 4
For patients receiving ertapenem without other risk factors for gastrointestinal complications, routine gastric protection with omeprazol is not justified, highlighting the importance of evidence-based practice in minimizing unnecessary medication use 1, 2